MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
63.88
+0.13 (+0.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close63.75
Open63.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range63.57 - 63.99
52 Week Range58.29 - 66.80
Volume10,304,201
Avg. Volume7,860,567
Market Cap174.22B
Beta0.94
PE Ratio (TTM)34.59
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.88 (2.95%)
Ex-Dividend Date2017-09-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal22 hours ago

    Merck to Shed Some U.S. Sales Reps to Cut Costs

    Merck & Co. said it is laying off nearly 7% of its U.S. workforce in a reorganization the company says will cut costs and shift focus to products with growth potential.

  • American City Business Journals22 hours ago

    Merck's sales force restructuring means 840 jobs lost

    Merck & Co. Inc. is planning to eliminate 1,800 exiting sales positions and create 960 new chronic care sales force jobs as part of a major restructuring. The action will not have an impact on Merck's campus in West Point, Pa., where the company has more than 9,000 employees — about 3,000 of whom work in research and another 3,000 in manufacturing. Merck (MRK), based in Kenilworth, N.J., has a total of about 68,000 employees.

  • Reutersyesterday

    Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

    By Deena Beasley (Reuters) - Drugmaker Merck & Co Inc (MRK.N), moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care ...

  • Reutersyesterday

    Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

    Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday. Three of Merck's U.S. sales teams will be cut: primary care, disease-focused endocrinology and hospital chronic care, spokeswoman Claire Gillespie said in an emailed statement.

  • Reutersyesterday

    Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care

    Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday. Three of Merck's U.S. sales teams will be cut, spokeswoman Claire Gillespie said in an emailed statement. The aim is "to better support changes in our business in the United States," Gillespie said.

  • Reuters2 days ago

    Merck cyber attack may cost insurers $275 million - Verisk's PCS

    Insurers could pay $275 million (209.06 million pounds) to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit. Merck, however, has not disclosed the magnitude of its uninsured losses from the "NotPetya" attack, which disrupted production of some Merck medicines and vaccines. "Merck has not yet fully quantified its losses, much less given any of its insurers an estimate of the total amount of those losses," Merck spokeswoman Claire Gillespie said in a statement.

  • Merck cyber attack may cost insurers $275 million: Verisk's PCS
    Reuters2 days ago

    Merck cyber attack may cost insurers $275 million: Verisk's PCS

    Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services unit. ...

  • 3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock
    InvestorPlace2 days ago

    3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock

    During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.

  • AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
    Zacks2 days ago

    AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

    AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks3 days ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Barrons.com3 days ago

    Merck: Is Keytruda a $16B Drug?

     Is Wall Street underestimating Keytruda? Shares of Merck& Co. ( MRK) popped today after Citigroup’s Andrew Baum upgraded the drug maker to Buy from Neutral, and hiked his price target from $65 a share to $72 a share, citing heightened expectations for the blockbuster cancer drug. It’s been a volatile 2017 for Merck.

  • TheStreet.com3 days ago

    Merck Stock Edges Higher as Citi Forecasts Strong Sales

    Citi analysts say Merck's Keytruda immunotherapy cancer drug will carry the company.

  • Benzinga3 days ago

    Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

    Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK ). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from ...

  • CNBC3 days ago

    Merck shares jump after Citi upgrade on stronger cancer drug sales

    Keytruda is an immunotherapy drug used in cancer treatments. Citi increased its peak Keytruda sales forecast on the drug to $16 billion from $9 billion.

  • Market Realist4 days ago

    Behind Merck’s Performance in 3Q17

    MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.

  • MarketWatch5 days ago

    Lost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening

    After months of headlines about astronomical drug prices, a funny thing’s happening — drug costs are plummeting.

  • Forbes5 days ago

    The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad

    The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.

  • Better Buy: AbbVie Inc. vs. Merck
    Motley Fool7 days ago

    Better Buy: AbbVie Inc. vs. Merck

    The deck is stacked in favor of one of these big pharma stocks. But which one?

  • Capital Cube8 days ago

    Merck & Co., Inc. – Value Analysis (NYSE:MRK) : October 13, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck & Co., Inc. a score of 47. Our analysis is based on comparing Merck & Co., Inc. with the following peers – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Merck & Co Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $11.76 billion.

  • Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
    InvestorPlace8 days ago

    Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

    Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.

  • There's no reason for investors to sell stocks now: NYSE trader
    Yahoo Finance Video2 days ago

    There's no reason for investors to sell stocks now: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss current headwinds for US equities, including the nomination of a new (or same) Federal Reserve Chair in a few weeks.

  • Buyers never came in that Monday in '87—it was chaos: NYSE trader
    Yahoo Finance Video2 days ago

    Buyers never came in that Monday in '87—it was chaos: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the New York Stock Exchange to discuss his firsthand account of what it was like on the floor that day.

  • I'm bullish on American Express and Verizon: NYSE trader
    Yahoo Finance Video2 days ago

    I'm bullish on American Express and Verizon: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the latest Q3 earnings. Disclosure: Verizon is Yahoo Finance's parent company, and Alan Valdes owns shares of the company.